First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi® (Lecanemab) Anti-Amyloid Therapy BOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:...Read more
As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated disease In all patients, the imlunestrant plus abemaciclib combination achieved a median PFS of 10.9 months, demonstrated a favorable OS...Read more
ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and the HER2 therapy trastuzumab The Actinium-225 alpha-emitter payload of ATNM-400 induced...Read more
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT enables development of AFib-RVR under sNDA pathway Milestone well-capitalized to launch and...Read more
FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against Neisseria gonorrhoeae infection in regions with a high prevalence of gonorrhea across five countries. NUZOLVENCE is one of the first new treatments approved by the FDA for...Read more
GAITHERSBURG, Md., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility to be added as the drug product manufacturing...Read more
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Eli Lilly | 18.12 1.80 | $1,027.50 |
| Ascendis Pharma | 10.26 4.88 | $220.42 |
| Ligand Pharmaceuticals | 6.42 3.51 | $189.55 |
| Movano Health | 6.31 202.89 | $9.42 |
| Vertex Pharmaceuticals | 6.11 1.37 | $452.04 |
| United Therapeutics | 5.48 1.12 | $493.99 |
| Bolt Biotherapeutics | 4.88 871.43 | $5.44 |
| UnitedHealth | 4.57 1.36 | $341.30 |
| Celcuity | 4.48 4.45 | $105.25 |
| Vera Therapeutics | 3.78 8.21 | $49.80 |
| Nektar Therapeutics | 3.58 7.00 | $54.70 |
| Lantheus | 3.52 5.58 | $66.62 |
| Protagonist Therapeutics | 3.10 3.36 | $95.35 |
| Galecto | 2.99 10.31 | $32.00 |
| Jazz Pharmaceuticals | 2.61 1.58 | $167.50 |
| Cytokinetics | 2.58 4.25 | $63.35 |
| Soleno Therapeutics | 2.51 5.07 | $52.00 |
| Cigna | 2.44 0.90 | $274.70 |
| Company | Volume | Last Trade |
|---|---|---|
| WORK Medical Technology | 959,635,251 | $0.12 |
| Tenaya Therapeutics | 135,813,555 | $0.84 |
| Applied Therapeutics | 133,947,267 | $0.12 |
| Rezolute | 123,320,455 | $1.67 |
| HeartBeam | 118,804,773 | $2.27 |
| Milestone Pharmaceuticals | 74,386,344 | $2.40 |
| Pfizer | 49,784,736 | $25.85 |
| BeyondSpring | 49,625,361 | $2.12 |
| Incannex Healthcare | 43,592,570 | $0.43 |
| ImmunityBio | 43,061,812 | $2.37 |
| Iovance Biotherapeutics | 35,112,791 | $2.20 |
| Intensity Therapeutics | 21,161,482 | $0.46 |
| Bristol-Myers Squibb | 18,744,678 | $52.41 |
| Moderna | 16,057,766 | $29.46 |
| Geron | 15,505,706 | $1.36 |
| Ocugen | 15,445,384 | $1.36 |
| Electromedical Technologies | 14,671,824 | $0.00 |
| Wave Life Sciences | 14,647,110 | $16.56 |
| Recursion | 14,614,448 | $4.33 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
